Efficacy and Safety of PCSK9 Inhibitors in Hypercholesterolemia Associated With Refractory Nephrotic Syndrome

INTRODUCTION: Treatment of hypercholesterolemia in refractory nephrotic syndrome remains a therapeutic challenge. There is not enough evidence supporting the efficacy of statins, and these drugs can be associated with an increased incidence of adverse effects. Herein we summarize our clinical experi...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Kidney Int Rep
Egile Nagusiak: Jatem, Elias, Lima, Joan, Montoro, Bruno, Torres-Bondia, Francisco, Segarra, Alfons
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Elsevier 2020
Gaiak:
Clinical Research
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC7783565/
https://ncbi.nlm.nih.gov/pubmed/33426389
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ekir.2020.09.046
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak